Related Experiment Video
Updated: Oct 13, 2026

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
Published on: April 5, 2011
Labetalol does not lengthen asystole during electroconvulsive therapy
P N Dannon1, I Iancu, S Hirschmann
1Chaim Sheba Medical Center, Psychiatry Division, Tel Hashomer, Israel.
Abstract:
Labetalol, a combined alpha- and beta-adrenergic blocker is often used to attenuate the transient increases in heart rate and blood pressure that accompany electroconvulsive therapy (ECT). It has been suggested that labetalol should not be administered during ECT without the protection provided by anticholinergic medications, because of its potential severe bradycardic effects. We present our experience with 32 patients from all age groups who received labetalol without anticholinergic treatment during ECT. None of the patients demonstrated adverse bradycardic effects. We conclude that administration of labetalol during ECT does not routinely require premedication with anticholinergic drugs and does not lengthen asystole.
More Related Videos
Related Concept Videos
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Cardiopulmonary Resuscitation IV: Pharmacological Management
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Electroconvulsive Therapy

